Sinopharm group reports modest revenue growth, net profit rise in Q3

China National Medicines Corp. (Sinopharm Group) announced its financial results for the third quarter of 2025, with operating income reaching CNY 13.75bn for the quarter, a 3.58% increase year-over-year. For the first nine months of 2025, cumulative operating income was CNY 39.38bn, up 3.56% from the prior year.

Net profit attributable to shareholders for the third quarter rose by 13.10% to CNY 543.72m. Year-to-date, this figure stands at CNY 1.49bn, representing a 0.74% increase compared to the same period in 2024. Basic earnings per share for the quarter were CNY 0.7206, with a year-to-date figure of CNY 1.9778.

Total assets as of September 30, 2025, were CNY 35.13bn, a slight increase from CNY 34.93bn at the end of the previous year. The weighted average return on net assets for the nine-month period was 8.50%, a decrease of 0.67 percentage points.